Hodgkin's Disease Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Hodgkin Disease Interventions:   Drug: Relatlimab;   Drug: Nivolumab Sponsor:   Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials

Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients
Condition:   Hodgkin Lymphoma Intervention:   Sponsor:   Federico II University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Hodgkin Disease Interventions:   Drug: Relatlimab;   Drug: Nivolumab Sponsor:   Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials

Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients
Condition:   Hodgkin Lymphoma Intervention:   Sponsor:   Federico II University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Hodgkin Disease Interventions:   Drug: Relatlimab;   Drug: Nivolumab Sponsor:   Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials

Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients
Condition:   Hodgkin Lymphoma Intervention:   Sponsor:   Federico II University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Hodgkin Disease Interventions:   Drug: Relatlimab;   Drug: Nivolumab Sponsor:   Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials

Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients
Condition:   Hodgkin Lymphoma Intervention:   Sponsor:   Federico II University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Hodgkin Disease Interventions:   Drug: Relatlimab;   Drug: Nivolumab Sponsor:   Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials

Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients
Condition:   Hodgkin Lymphoma Intervention:   Sponsor:   Federico II University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Hodgkin Disease Interventions:   Drug: Relatlimab;   Drug: Nivolumab Sponsor:   Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2022 Category: Research Source Type: clinical trials

A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma
Condition:   Hodgkin Disease Lymphoma Interventions:   Drug: Penpulimab;   Drug: Investigator's choice of Chemotherapy Sponsors:   Akeso;   Beijing Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 17, 2022 Category: Research Source Type: clinical trials